SCHEMBL3522211

SCHEMBL3522211

Cc1nn(C)c(Cl)c1CN1CCO[C@H](C(=O)N(Cc2ccc3c(c2)OCCCO3)CC(C)C)C1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PROKR2 Q8NFJ6 4/20 0.56
KMT2A Q03164 6/20 0.41
ALDH1A1 P00352 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.36
ATM Q13315 1/20 0.36
KDM4E B2RXH2 4/20 0.36
GRN P28799 1/20 0.36
SORT1 Q99523 1/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MEN1 O00255 3/20 0.35
SHMT2 P34897 1/20 0.34
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3516858 1.00 PROKR2 (0.56) PROKR2KMT2AALDH1A1L3MBTL1ATM
SCHEMBL3519332 0.98 PROKR2 (0.54) PROKR2KMT2AALDH1A1L3MBTL1ATM
SCHEMBL3518764 0.98 PROKR2 (0.53) PROKR2KMT2AALDH1A1L3MBTL1ATM
SCHEMBL3518537 0.93 PROKR2 (0.52) PROKR2KMT2AALDH1A1L3MBTL1ATM
SCHEMBL3516521 0.93 PROKR2 (0.54) PROKR2KMT2AALDH1A1KDM4EGRN
SCHEMBL3520053 0.90 PROKR2 (0.57) PROKR2KMT2AALDH1A1KDM4EHPGD
SCHEMBL3522275 0.86 PROKR2 (0.58) PROKR2KMT2AALDH1A1KDM4EGRN
SCHEMBL3522266 0.86 PROKR2 (0.55) PROKR2KMT2AALDH1A1L3MBTL1KDM4E
SCHEMBL3516648 0.85 PROKR2 (0.55) PROKR2KMT2AALDH1A1KDM4EGRN
SCHEMBL3518160 0.84 PROKR2 (0.62) PROKR2KMT2AALDH1A1KDM4EGRN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1959959-B1 MORPHOLINE CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME (US) 2013-04-10 EP claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US claimed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US claimed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-7855201-B2 Morpholine carboxamide prokineticin receptor antagonists Merck Sharp & Dohme. Corp. (US) 2010-12-21 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists MERCK SHARP & DOHME LLC 2009-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306076-A1 Morpholine Carboxamide Prokineticin Receptor Antagonists PROKR2, PROKR1, NTSR2 PROKR2 1/4885KMT2A 2847/4885ALDH1A1 4629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.